Schering Corporation

Schering-plough Corporation

Merck Sharp + Dohme Corp.

William Kreutner

Anil K Saksena

Michael J Green

Ho-Jane Shue

Arthur G Taveras

David J Blythin

Younong Yu

Purakkattle J Biju

Shen-Chun Kuo

Jianhua Chao

Marvin I Siegel

Daniel Lundell

John A Hey

Robert Schleimer

Loretta A Bober

Jay S Fine

Richard W Chapman

Domenic G Iezzoni

James P Jakway

John Schroeder

Motasim Billah

Arnold Lash

Gary Binder

Sultan Aziz

Donald Bolser

James Jakway

Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).

Treatment of chemokine mediated diseases

Methods of inhibiting the generation of pro-inflammatory cytokines such as IL-4 and IL-13 in a human patient in need of such inhibiting are disclosed.

Inhibition of cytokine generation

The present invention provides methods of treatment of mental and vascular disorders. In one embodiment, the present invention contemplates the administration of an anti-allergic medication to reduce a patient's symptoms of mental or vascular disorder. The patient may or may not suffer from allergic responses. Likewise, the methods of the present invention may be used to reduce or prevent the symptoms of a mental or vascular disorder. In a preferred embodiment, the anti-allergic medication is a non-sedating or low-sedating antihistamine such as loratadine or desloratadine.

Methods for the treatment of vascular disorders

The present invention provides methods of treatment of mental disorders comprising administering the anti-allergic medication loratadine or a metabolite thereof to reduce a patient's symptoms of a mental disorder.

Methods for the treatment of mental disorders

2-substituted morpholine and thiomorpholine derivatives as GABA-B

Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H.sub.1 receptor antagonist; together with (b) a sufficient amount of a histamine H.sub.3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or separately in the same or different dosage forms to maintain therapeutic systemic levels of both components.

Treatment of upper airway allergic responses

A method for treating cough in a mammal comprising administering to said mammal an anti-tussive effective amount of a GABA-B selective agonist such as ##STR1## is described.

Use of GABA-B selective agonists as anti-tussive agents

Forskolin and its disclosed derivatives are useful as antiallergic agents. Certain of the derivatives are novel.

Method for treating allergic reactions with Forskolin

A method for producing bronchodilation in a mammal is disclosed. Composition for use in said method are also described.

Methods of inducing bronchodilation

Method for treating allergic reactions with forskolin

Growing community of inventors

West Paterson, NJ, United States of America

William Kreutner